TENX
NASDAQ · Biotechnology
Tenax Therapeutics Inc
$12.73
+0.37 (+2.99%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.99M | 20.76M | 15.61M |
| Net Income | 4.98M | 4.98M | 3.68M |
| EPS | — | — | — |
| Profit Margin | 24.9% | 24.0% | 23.6% |
| Rev Growth | +24.3% | +21.0% | +20.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 39.93M | 39.83M | 42.30M |
| Total Equity | 49.49M | 55.25M | 49.51M |
| D/E Ratio | 0.81 | 0.72 | 0.85 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.23M | 8.32M | 5.37M |
| Free Cash Flow | 5.95M | 3.82M | 3.47M |